Status:
UNKNOWN
Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer
Lead Sponsor:
Sunnybrook Health Sciences Centre
Conditions:
Breast Cancer
Invasive Ductal Breast Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasi...
Detailed Description
The specific aims of the study are to (1) to identify clinicopathomic biomarkers from pre-treatment core biopsies that are predictive of response to neoadjuvant chemotherapy, (2) determine patterns of...
Eligibility Criteria
Inclusion
- Participants must be men and women age 18+
- Biopsy-confirmed diagnosis of invasive breast cancer; (ER+/-, PR+/-, HER2+/-)
- Any state of disease as described by AJCC v7 criteria
- Participants must have received and completed neoadjuvant chemotherapy
Exclusion
- Participants who had other primary cancers prior to breast cancer
Key Trial Info
Start Date :
August 30 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2024
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT04021069
Start Date
August 30 2018
End Date
August 30 2024
Last Update
July 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N3M5